RA
NBIX icon

Rise Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Rise Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-243
Closed -$34.1K – 963
2025
Q3 		$34.1K Hold
243
– – 0.01% 345
2025
Q2 		$30.5K Hold
243
– – 0.01% 340
2025
Q1 		$26.9K Sell
243
-99
-29% -$12.5K 0.01% 362
2024
Q4 		$46.7K Sell
342
-10
-3% -$1.24K 0.02% 244
2024
Q3 		$40.6K Hold
352
– – 0.02% 296
2024
Q2 		$48.5K Hold
352
– – 0.03% 239
2024
Q1 		$48.5K Buy
352
+300
+577% +$41K 0.03% 236
2023
Q4 		$6.85K Hold
52
– – ﹤0.01% 356
2023
Q3 		$5.85K Sell
52
-22
-30% -$2.32K ﹤0.01% 365
2023
Q2 		$6.98K Sell
74
-2
-3% -$195 0.01% 388
2023
Q1 		$7.69K Buy
76
+2
+3% +$208 0.01% 400
2022
Q4 		$8.84K Hold
74
– – 0.01% 368
2022
Q3 		$8K Hold
74
– – 0.01% 373
2022
Q2 		$7K Hold
74
– – 0.01% 399
2022
Q1 		$7K Buy
74
+21
+40% +$1.78K 0.01% 375
2021
Q4 		$4.51K Buy
+53
New +$4.88K ﹤0.01% 418

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Rise Advisors's NBIX Position: Q4 2025 in Review

Rise Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 243 shares — an estimated $34.1K sold.

Rise Advisors first reported a position in NBIX in Q4 2021 and held it in 16 quarters. The position peaked at $48.5K in Q1 2024. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Rise Advisors reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 243 Neurocrine Biosciences shares in Q4 2025, an estimated $34.1K.
  • Rise Advisors first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 16 quarters.
  • Rise Advisors's Neurocrine Biosciences position peaked at $48.5K in Q1 2024.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.